tbuckley/cabot-search huggingface dataset:
Abstract 19705: PLTP Deficiency Attenuates High Fat Diet Induced Obesity and Insulin Resistance
Authors: Guohua Song, Chuanlong Zong, Mingzhu Shao, Yang Yu, Shoudong Guo, Qian Liu, Xinnong Wang, Phoebe Lee, Yi Luo, Zheng Guo, Xian-Cheng Jiang, Shucun Qin
Journal: Circulation (2017)

Introduction: Increased phospholipid transfer protein (PLTP) activity has been found to be associated with obesity, and metabolic syndrome in humans. Hypothesis: PLTP might have a direct effect on insulin sensitivity and obesity. Methods: Here we analyzed the effect by using PLTP knockout (PLTP-/-) mouse model. Results: Although, PLTP-/- mice have normal body-weight-gain under chow diet, these mice were protected from high-fat-diet-induced obesity and insulin resistance, compared with wild type mice. In order to understand the mechanism, we evaluated insulin receptor and Akt activation and found that PLTP deficiency significantly enhanced phosphorylated insulin receptor and Akt levels in high-fat-diet fed mouse livers, adipose tissues, and muscles after insulin stimulation, while total Akt and insulin receptor levels were unchanged. Moreover, we found that the deficiency induced significantly more GLUT4 immunostaining in the plasma membranes of adipocytes and muscle cells after insulin stimulation. Finall...
Inflammation in SLE-PAH: good news or not?
Authors: Junyan Qian, Mengtao Li, Jiuliang Zhao, Qian Wang, Zhuang Tian, Xiaofeng Zeng
Journal: Annals of the Rheumatic Diseases (2018)

Figure 1 (A) Survival curves of patients with SLE-PAH in two different weighted score groups.(B) TGA curves of patients with SLE-PAH in two different weighted score groups.on August 2,
Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice
Authors: Angela M. Fowler, William W. Tang, Matthew P. Young, Anila Mamidi, Karla M. Viramontes, Melanie D. McCauley, Aaron F. Carlin, Robert T. Schooley, Jesica Swanstrom, Ralph S. Baric, Jennifer Govero, Michael S. Diamond, Sujan Shresta
Journal: Cell Host & Microbe (2018)

Antibody (Ab)-dependent enhancement can exacerbate dengue virus (DENV) infection due to cross-reactive Abs from an initial DENV infection, facilitating replication of a second DENV. Zika virus (ZIKV) emerged in DENV-endemic areas, raising questions about whether existing immunity could affect these related flaviviruses. We show that mice born with circulating maternal Abs against ZIKV develop severe disease upon DENV infection. Compared with pups of naive mothers, those born to ZIKV-immune mice lacking type I interferon receptor in myeloid cells (LysMCre+Ifnar1fl/fl) exhibit heightened disease and viremia upon DENV infection. Passive transfer of IgG isolated from mice born to ZIKV-immune mothers resulted in increased viremia in naive recipient mice. Treatment with Abs blocking inflammatory cytokine tumor necrosis factor linked to DENV disease or Abs blocking DENV entry improved survival of DENV-infected mice born to ZIKV-immune mothers. Thus, the maternal Ab response to ZIKV infection or vaccination might predispose to severe dengue disease in infants.
CircSLC3A2 functions as an oncogenic factor in hepatocellular carcinoma by sponging miR-490-3p and regulating PPM1F expression
Authors: Hongjian Wang, Wei Chen, Ming Jin, Lidan Hou, Xiaoyu Chen, Rui Zhang, Jing Zhang, Jinshui Zhu
Journal: Molecular Cancer (2018)

Non-coding RNAs (ncRNAs) have been reported to participate in tumor progression by regulating gene expression. Previous studies showed that protein phosphatase Mg2+/Mn2+ dependent 1F (PPM1F) acts a dual role in cancer growth and metastasis. But, the underlying mechanisms by which ncRNAs regulate PPM1F expression in hepatocellular carcinoma (HCC) are poorly understood. The association between PPM1F or miR-490-3p expression and clinicopathological features and prognosis in patients with HCC was analyzed by TCGA RNA-sequencing data. CircSLC3A2 was identified to bind with miR-490-3p by bioinformatic analysis, and the binding sites between miR-490-3p and PPM1F or circSLC3A2 were confirmed by dual luciferase report and RNA immunoprecipitation (RIP) assays. The localization and clinical significance of miR-490-3p and circSLC3A2 in patients with HCC were investigated by fluorescence in situ hybridization (FISH). MTT, Agar, and Transwell assays were conducted to evaluate the effects of miR-490-3p or circSLC3A2 on cell proliferation and invasive potential. The expression of PPM1F or miR-490-3p was associated with poor survival and tumor recurrence, and acted as an independent prognostic factor in patients with HCC. Re-expression of miR-490-3p inhibited HCC cell proliferation and invasion by targeting PPM1F, but its inhibitor reversed these effects. Moreover, circSLC3A2, predominantly localized in the cytoplasm, exhibited an oncogenic role by sponging miR-490-3p and regulating PPM1F expression, and harbored a positive correlation with poor survival in patients with HCC. CircSLC3A2 acts as an oncogenic factor in HCC by sponging miR-490-3p and regulating PPM1F expression.
Efficacy and Safety of Besifovir Dipivoxil Maleate Compared With Tenofovir Disoproxil Fumarate in Treatment of Chronic Hepatitis B Virus Infection
Authors: Sang Hoon Ahn, Won Kim, Young Kul Jung, Jin Mo Yang, Jae Young Jang, Yong Oh Kweon, Yong Kyun Cho, Yoon Jun Kim, Gun Young Hong, Dong Joon Kim, Soon Ho Um, Joo Hyun Sohn, Jin Woo Lee, Sung Jae Park, Byung Seok Lee, Ju Hyun Kim, Hong Soo Kim, Seung Kew Yoon, Moon Young Kim, Hyung Joon Yim, Kwan Sik Lee, Young Suk Lim, Wan Sik Lee, Neung Hwa Park, So Young Jin, Kyun-Hwan Kim, Won Choi, Kwang-Hyub Han
Journal: Clinical Gastroenterology and Hepatology (2018)

Besifovir dipivoxil maleate (BSV) has activity against hepatitis B virus (HBV). We performed a phase 3 study to compare the antiviral efficacy and safety of BSV vs tenofovir disoproxil fumarate (TDF) in patients with chronic HBV infection in Korea.We conducted a double-blind, non-inferiority trial of 197 patients with chronic HBV infection at 22 sites in South Korea, from November 2013 through February 2016. Patients were randomly assigned to groups given BSV (150 mg, n = 99) or TDF (300 mg, n = 98) for 48 weeks. We evaluated virologic responses to therapy (HBV DNA <69 IU/mL or 400 copies/ml), bone mineral density (BMD), and renal outcomes for safety analysis. The main efficacy endpoint was the proportion of patients with a virologic response at week 48. After 48 weeks, TDF was switched to BSV (150 mg) for an additional 48 weeks.After 48 weeks of treatment, 80.9% of patients given BSV and 84.9% of patients given TDF met the efficacy endpoint, indicating the non-inferiority of BSV to TDF. At week 96, 87.2% of patients in the BSV-BSV and 85.7% of patients in the TDF-BSV had a virologic response. At week 48, changes in hip and spine BMD differed significantly between the BSV and TDF groups, whereas the estimated glomerular filtration rate in the TDF group was significantly lower than that in the BSV group. However, at 96 weeks, there were no significant differences in BMD and estimated glomerular filtration rate between the BSV-BSV and TDF-BSV groups.BSV has antiviral efficacy comparable to that of TDF after 48 weeks of treatment, with durable effects for 96 weeks. BSV has a better safety profile than TDF, in terms of bone and renal outcomes. ClinicalTrials.gov no: NCT01937806.
Effects of the Learning Together intervention on bullying and aggression in English secondary schools (INCLUSIVE): a cluster randomised controlled trial
Authors: Chris Bonell, Elizabeth Allen, Emily Warren, Jennifer McGowan, Leonardo Bevilacqua, Farah Jamal, Rosa Legood, Meg Wiggins, Charles Opondo, Anne Mathiot, Jo Sturgess, Adam Fletcher, Zia Sadique, Diana Elbourne, Deborah Christie, Lyndal Bond, Stephen Scott, Russell M Viner
Journal: The Lancet (2018)

Bullying, aggression, and violence among children and young people are some of the most consequential public mental health problems. We tested the Learning Together intervention, which involved students in efforts to modify their school environment using restorative practice and by developing social and emotional skills.We did a cluster randomised trial, with economic and process evaluations, of the Learning Together intervention compared with standard practice (controls) over 3 years in secondary schools in south-east England. Learning Together consisted of staff training in restorative practice; convening and facilitating a school action group; and a student social and emotional skills curriculum. Primary outcomes were self-reported experience of bullying victimisation (Gatehouse Bullying Scale; GBS) and perpetration of aggression (Edinburgh Study of Youth Transitions and Crime (ESYTC) school misbehaviour subscale) measured at 36 months. We analysed data using intention-to-treat longitudinal mixed-effects models. This trial was registered with the ISRCTN registry (10751359).We included 40 schools (20 in each group); no schools withdrew. 6667 (93·6%) of 7121 students participated at baseline and 5960 (83·3%) of 7154 at 36 months. Mean GBS bullying score at 36 months was 0·34 (SE 0·02) in the control group versus 0·29 (SE 0·02) in the intervention group, with a significant adjusted mean difference (-0·03, 95% CI -0·06 to -0·001; adjusted effect size -0·08). Mean ESYTC score at 36 months was 4·33 (SE 0·20) in the control group versus 4·04 (0·21) in the intervention group, with no evidence of a difference between groups (adjusted difference -0·13, 95% CI -0·43 to 0·18; adjusted effect size -0·03). Costs were an additional £58 per pupil in intervention schools than in control schools.Learning Together had small but significant effects on bullying, which could be important for public health, but no effect on aggression. Interventions to promote student health by modifying the whole-school environment are likely to be one of the most feasible and efficient ways of addressing closely related risk and health outcomes in children and young people.National Institute for Health Research, Educational Endowment Foundation.
Abstract 13321: Usefulness of Classification and Regression Trees (CART) Analysis to Determine Optimal Ranges of Clinical Parameters Associated With Prognosis after Acute Myocardial Infarction
Authors: Sen Matsumoto, Yasuhiko Sakata, Daisaku Nakatani, Shinichiro Suna, Masaya Usami, Masahiko Hara, Tetsuhisa Kitamura, Tatsuya Sasaki, Hiroshi Sato, Shinsuke Nanto, Masatsugu Hori, Issei Komuro
Journal: Circulation (2013)

Background: With conventional statistical strategies such as Receiver Operating Curve (ROC) methods, it is difficult to determine optimal target ranges in clinical parameters having U-shaped, but n...
Abstract 17997: Metformin Prevents the Development of Cardiomyopathy and Cardiac Dysfunction in ‰Diabetogenic” Diet-fed BTBRob/+ Mice
Authors: Jinkyu Kim, Tomasz A Wietecha, Dao-Fu Dai, Brittany Sullivan, Antonio Sta Teresa, Kelly L Hudkins, Charles E Alpers, Kevin D O'Brien
Journal: Circulation (2012)

Background: We recently have shown that, when fed a high-fat, high sucrose “diabetogenic” diet (DD) for 16 weeks, BTBR mice heterozygous for leptin deficiency (BTBRob/+) develop insulin resistance ...
Author Correction: Impaired perceptual learning in a mouse model of Fragile X syndrome is mediated by parvalbumin neuron dysfunction and is reversible
Authors: Anubhuti Goel, Daniel A. Cantu, Janna Guilfoyle, Gunvant R. Chaudhari, Aditi Newadkar, Barbara Todisco, Diego de Alba, Nazim Kourdougli, Lauren M. Schmitt, Ernest Pedapati, Craig A. Erickson, Carlos Portera-Cailliau
Journal: Nature Neuroscience (2018)
Magic Mouthwash for Oral Mucositis
Authors: Angad S. Uberoi, Timothy J. Brown, Arjun Gupta
Journal: JAMA Internal Medicine (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Non-Hodgkin’s lymphoma of the brainstem: a case report and discussion.
Authors: Cigall Kadoch, Richard H. Matthews
Journal: Cancer Research (2006)

5319  Primary central nervous system lymphoma (PCNSL) is an aggressive intracranial malignancy. > 90% are B-cell Non-Hodgkin’s Lymphoma (NHL). Treatment for PCNSL has been whole brain irradiation, often yielding complete response and ameliorated symptoms, but resulting in median survival of only 12-18 months and a 5-year survival rate  /= 60 yo compared to 50.4 months in pts
Prehospital Advanced Life Support for Out-of-Hospital Cardiac Arrest in Blunt Trauma Patients
Authors: Vikram Aakash Khanna, Swathikan Chidambaram, En Lin Goh
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Study raises hopes of minimising risk of life threatening peanut allergy reactions
Authors: Ingrid Torjesen
Journal: BMJ (2018)

Children and young people with peanut allergy exposed to gradually increasing doses of peanut allergen were then able to ingest far higher doses of peanut protein, a randomised trial has found.

The findings, published in the New England Journal of Medicine ,1 raise hopes that a desensitisation treatment strategy could be developed to reduce the risk of severe fatal reactions that can occur after accidental exposure to allergens. These can be fatal as in the case of Natasha Ednan-Laperouse, who died after eating a baguette from the catering outlet Pret-a-Manger that contained sesame to which she was allergic.

The trial, funded by Aimmune Therapeutics, included 551 people aged 4 …
Elite football teams that do not have a winter break lose on average 303 player-days more per season to injuries than those teams that do: a comparison among 35 professional European teams
Authors: Jan Ekstrand, Armin Spreco, Michael Davison
Journal: British Journal of Sports Medicine (2018)

To compare injury rates among professional men's football teams that have a winter break in their league season schedule with corresponding rates in teams that do not.56 football teams from 15 European countries were prospectively followed for seven seasons (2010/2011-2016/2017)-a total of 155 team-seasons. Individual training, match exposure and time-loss injuries were registered. Four different injury rates were analysed over four periods within the season, and linear regression was performed on team-level data to analyse the effect of winter break on each of the injury rates. Crude analyses and analyses adjusted for climatic region were performed.9660 injuries were reported during 1 447 011 exposure hours. English teams had no winter break scheduled in the season calendar: the other European teams had a mean winter break scheduled for 10.0 days. Teams without a winter break lost on average 303 days more per season due to injuries than teams with a winter break during the whole season (p<0.001). The results were similar across the three periods August-December (p=0.013), January-March (p<0.001) and April-May (p=0.050). Teams without a winter break also had a higher incidence of severe injuries than teams with a winter break during the whole season (2.1 severe injuries more per season for teams without a winter break, p=0.002), as well as during the period January-March (p=0.003). A winter break was not associated with higher team training attendance or team match availability. Climatic region was also associated with injury rates.The absence of a scheduled winter break was associated with a higher injury burden, both before and during the two periods following the time that many European teams take a winter break. Teams without a winter break (English clubs) had a higher incidence of severe injuries following the time of the year that other teams (other European clubs) had their scheduled break.
Happy ever after? A new assessment tool for long-term noninvasive ventilation: the S<sup>3</sup>-NIV questionnaire
Authors: Anita K. Simonds
Journal: European Respiratory Journal (2018)

Over a decade ago, the Eurovent study [1] examined the practice of home mechanical ventilation (HMV) in Europe and showed that the prevalence was increasing and indications for use were growing, but that there were wide inequalities in provision. Services offered varied considerably between countries [2], with no obvious standardisation of care. Subsequent prevalence work worldwide has confirmed the expansion of this area, and randomised trials have established clearer indications for initiation of long-term noninvasive ventilation (NIV), e.g. in chronic obstructive pulmonary disease (COPD) [3–5] and motor neurone disease/amyotrophic lateral sclerosis [6]. Outcomes were originally measured by survival and physiological measures. The S3-NIV questionnaire provides a new simple assessment tool for long-term noninvasive ventilation <http://ow.ly/BWsY30miiJ6>
Abstract 21142: Ultrafiltration on CPB Predicts AKI and Transfusion
Authors: Michael Manning, Yi-Ju Li, Dean Linder, John Haney, Yi-Hung Wu, Mihai Podgoreanu, Jacob Schroder, Madhav Swaminathan, Carmelo Milano, Ian Welsby, Mani Daneshmand, Mark Stafford-Smith, Kamrouz Ghadimi
Journal: Circulation (2017)

Introduction: Postoperative acute kidney injury (AKI) confers poor outcomes after cardiac surgery. Conventional ultrafiltration (CUF) is performed on cardiopulmonary bypass (CPB) to raise hematocrit, avoid intraoperative blood transfusion, and provide renal protection. These protective effects remain unclear with high CUF volumes, which may cause hypovolemia and renal hypoperfusion. Hypothesis: Higher CUF volumes will be associated with increased AKI and poor outcomes. Methods: Retrospective analysis of 1,791 consecutive patients undergoing cardiac surgery (CABG, CABG/Valve, Valve only) was performed between June 2013 and December 2015. Institutional CPB protocol with CUF was used during all cases. Uni- and multivariable logistic regression analyses determined predictors for AKI. CUF volume analyses were performed, defined by two extreme quartiles or by Youden index derived from ROC analysis, and compared for their effect on AKI rate. Mortality data was acquired from the Social Security Administration’s Death Master File through 1 year after index surgery. Results: CUF volume independently predicted AKI (p&lt;0.0001)(Fig 1A). Critical CUF volume associated with AKI, defined by 3 rd quartile, was &gt; 2,900 ml (OR=1.72, 95% CI 1.25, 2.38) and defined by Youden index, was &gt; 2,239 ml, (OR=1.52, 95% CI 1.22, 1.89). While associated with increased intraoperative blood transfusion volume (p=0.002), CUF volume in AKI patients (N=903) predicted increased ICU (p&lt;0.001) and hospital LOS (p&lt;0.001). AKI incidence was associated with increased 30-day mortality (HR=2.78, 95% CI 1.06 - 7.27; p=0.037) but no significant difference in survival was seen when AKI group was stratified by CUF volume (Fig 1B), based on a small number of events (N=25). AKI did not yield significant HR for death between 30 days - 1 year. Conclusions: CUF volume removal during CPB predicted blood transfusion requirements, postoperative AKI, and ICU/Hospital LOS, while AKI predicted 30-day mortality.
No relevant pharmacokinetic drug–drug interaction between nintedanib and pirfenidone
Authors: Luca Richeldi, Sophie Fletcher, Huzaifa Adamali, Nazia Chaudhuri, Sabrina Wiebe, Sven Wind, Kathrin Hohl, Andrew Baker, Rozsa Schlenker-Herceg, Susanne Stowasser, Toby M. Maher
Journal: European Respiratory Journal (2018)

Nintedanib and pirfenidone are approved treatments for idiopathic pulmonary fibrosis (IPF). This open-label, two-group trial investigated the pharmacokinetic drug-drug interaction between these two drugs in patients with IPF.Subjects not treated with antifibrotics at screening (group 1, n=20) received a single nintedanib dose (150 mg) followed by pirfenidone (titrated to 801 mg thrice daily) for 3 weeks, with a further single nintedanib dose (150 mg) on the last day (day 23). Subjects treated with pirfenidone at screening (group 2, n=17) continued to receive pirfenidone alone (801 mg thrice daily) for 7 days, then co-administered with nintedanib (150 mg twice daily) for a further 7 days, before single doses of both treatments on day 16.In group 1, adjusted geometric mean (gMean) ratios (with/without pirfenidone) were 88.6% and 80.6% for nintedanib area under the plasma concentration-time curve (AUC) and maximum plasma concentration (Cmax), respectively. In group 2, gMean ratios (with/without nintedanib) were 97.2% and 99.5% for pirfenidone AUC and Cmax, respectively. For all parameters, the 90% confidence intervals included 100%, suggesting similar exposure for administration alone and when co-administered. Both treatments were well tolerated.These data indicate there is no relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone when co-administered in IPF patients.